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generis right as shaped within the current European legal system.  
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“Adiós Sui Géneris”. A study of the legal feasibility 
of the sui generis right in the context of research 
biobanks1 
 
 
 
SUMMARY: 1. Introduction – 2. The legal protection of the database in 
Europe - 3 . Biobanks and the sui generis right: a possible relationship? - 4. 
Conclusion 
 
 
1. Introduction 
Over the last years, biomedical research has experienced 
terrific development, thanks to the advancements of the information 
and communication technology (ICT), the creation of research 
infrastructures, such as biobanks, and the increasing investments, 
mainly coming from the public sector. At the core of this type of 
research, there is the bioinformation: the growth of the biomedical 
sector dramatically depends both on the availability and reliability of 
data and biomaterials, and on the possibility of enhancing the data 
sharing. 
  In this scenario, the role of technology has been twofold: it 
has profoundly changed both the traditional research methods and 
the social dynamics towards data sharing. On the one hand, new 
sophisticated instrumentation devices have allowed a richer and 
more detailed molecular analysis of biological and DNA samples, 
producing a huge amount of data and information almost 
unimaginable twenty years ago. On the other hand, data, 
information, materials and scientific findings are captured, 
summarized, and, above all, shared in a more efficient and quick way 
due to the ICT, which fosters the information retrieval, the 
comparison between communities of practices, the validation of the 
results, etc. That is why the container of this information, namely a 
database, is growing in importance for the scientific community and 
it is changing the social norms governing it. As Paul David pointed 
out: «for open science research communities, databases are dynamic 
tools, not merely static sources to be passively consulted; they are 
formed and kept effective through an interactive process of 
                                                 
1
 The idea for this paper grew out of a conversation that I had with Thomas 
Margoni during a research period at the IViR (University of Amsterdam). I wish 
to thank him for his valuable suggestions and encouragement in deepening this 
issue. 
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examination, error-correction, updating, and incremental elaboration 
that engages the critical expertise of many individuals in the 
communities of researchers who co-operate in developing, certifying 
and maintaining these research instruments. Thus, in many contexts 
the value of the information to users is enhanced by the very fact 
that its use has been, and will continue to be shared with other 
researchers»2. 
  All the aforementioned factors are of paramount importance 
in a sector, such as the biomedical one, which is characterized by the 
interdisciplinarity and the interaction among professionals with 
different scientific backgrounds, often located miles away one from 
each other.  
  Although in the last few years a significant improvement in 
the quantity and quality of the information’s production as well as a 
strengthening of the tools to share it have occurred, there are still 
some problems that hinder the exploitation of this tremendous 
potential. The obstacles are mainly of technological, socio-
economical and legal nature.  
  Firstly, from the technological point of view, the data sharing 
may be hampered by the lack of common standards or 
interoperability among systems, and by the problems of web-
semantic and web-ontology that are currently at the center of the 
bioinformatics’ debate3.  
  Secondly, with all due respect to Merton, a researcher is not 
inclined to voluntarily share his or her collection of data and 
preliminary results before they have been published or patented. An 
archive of data is a basic resource on which the researcher’s 
academic prestige, his or her career progression, the chance to win 
grants, or the ability to support his or her research group can 
depend. For all these reasons, it is easy to understand why these 
resources are a little “treasure” for the one who sets them up and 
why they are not so freely shared4.  
  Lastly, the legal regime is also making more difficult to 
promote the data sharing and the spread of knowledge. We are 
facing a phenomenon which has been labeled by James Boyle as «the 
                                                 
2 DAVID, Paul Alan, A Tragedy of the Public Knowledge «commons»?: Global 
Science, Intellectual Property and the Digital Technology Boomerang”, SIEPR 
Discussion Paper No. 00-02, 2001, available at: 
http://www.stanford.edu/group/siepr/cgi-
bin/siepr/?q=system/files/shared/pubs/papers/pdf/00-02.pdf 
3 KANGUEANE, Pandjassarame, Bioinformation Discovery: Data to 
Knowledge in Biology, Springer-Verlag, New York, USA, 2009. 
4 GITTER, Donna, “The Challenges of Achieving Open Source Sharing of 
Biobank Data”, Comparative Issues in the Governance of Research Biobanks, 
PASCUZZI, Giovanni/ IZZO, Umberto/ MACILOTTI, Matteo (Eds.), 
Springer, Germany, 2013, pp. 165 ff. 
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second enclosure movement»5, where intellectual property rights 
(IPRs) have expanded so fast and beyond control, thus undermining 
the boundaries of the public domain6: the case of the recognition of 
audiovisual rights for sport events, the legal protection of domain 
name, the ban of mash up, the grant of a patent for gesture movies 
(sic!)7 are a manifestation of this trend. Such an “enclosure” is also 
taking place in the field of biomedical research. The human genome 
offers two valid examples in this sense: (a) an isolated gene can be 
patented8, and (b) an assemblage of facts, such as a collection of 
DNA samples and related data, can be covered by copyright or sui 
generis right according to the European law. 
  The expansion of the notion of patent-eligible subject matter 
is critical in the biomedical field, but the swelling of copyright and sui 
generis right risks to jeopardize the free flow of information in a more 
silent and subtle way. This is particular evident if we consider 
biobanks. They are powerful tools and organizational structures, 
which are crucial for the biomedical research, as they provide 
essential information: they systematically collect and store human 
biological samples in a professional way and according to high 
standards of quality and safety9. These samples are a source of 
information (genetic, health, biochemical, molecular information) 
and they are generally linked to data coming from other sources, 
                                                 
5 BOYLE, James, “The second enclosure movement and the construction of the 
public domain”, Law and contemporary problems, Duke Law School, Núm. 1-2, 
Vol. 66, Durham, USA, 2003, pp. 33 y ss. See also ID., The public domain: 
enclosing the commons of the mind, Yale University Press, New Haven, USA, 
2008. 
6  RESTA, Giorgio, Diritti esclusivi e nuovi beni immateriali, Wolters Kluwer 
Italia, Milano, Italy, 2010. 
7 ORDING, Bas/ JOBS, Stephen, “Gesture Movies”, available at 
http://www.google.it/patents?id=ySjIAAAAEBAJ. 
8 With regards to the the gene patents, it is relevant to mention the recent 
opinion of the US Supreme Court on the “Myriad saga”. The issue at stake was 
precisely about the patentability of the sequence of two genes, BRCA-1 and 
BRCA-2, which are two human caretaker genes linked to breast and ovarian 
cancer. The Court unanimously ruled that DNA as such is a product of nature 
and, as a consequence, it is not patent eligible; instead, the cDNA (i.e. the 
synthesized DNA deprived of the segment that do not code for proteins) is a 
patentable subject's matter. This decision cannot be considered as an overruling 
of the precedent Diamond v. Chakrabarty (in fact, the Court confirmed the 
precedent, see p. 11), but it undoubtedly reduces the area of the gene 
patentability. See Association for Molecular Pathology v. Myriad Genetics, Inc., 
569 U. S. ____ (2013), slip opinion available at: 
http://www.supremecourt.gov/opinions/12pdf/12-398_1b7d.pdf 
9 For a more thorough definition, see ORFAO DE MATOS, Alberto, 
“Biobancos”, Enciclopedia de bioderecho y bioética, ROMEO CASABONA, 
Carlos María (Ed.), Comares-Roche Institute, España, Vol. 1, 2011; ROMEO 
MALANDA, Sergio, “Biobancos”, Enciclopedia de bioderecho y bioética, 
ROMEO CASABONA, Carlos María (Ed.), Comares-Roche Institute, España, 
Vol. 1, 2011. 
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such as the clinical history of an individual person. So, basically, 
biobanks have, or can be considered as, databases and, for this 
reason, are eligible for copyright or sui generis protection. 
  Nevertheless, looking at the uniqueness of human genome 
and the scarcity of tissues, such a protection can produce a typical 
monopolistic effect: due to the restrictions to access, use and share 
of basic and pre-competitive information, the copyright or sui generis 
protection can create negative externalities for the whole society and 
the progress of future research. In fact, sui generis right has been 
criticized by legal scholars for its anticompetitive nature and its 
inefficiencies10: it represents a European anomaly that should be 
repealed for economical and social reasons11. The value of that 
opinion can be observed from a de iure condendo perspective; however, 
in this paper a different aspect is stressed.  
Many scholars argue too easily that a biobank can get the sui generis 
right protection, but they do not examine deeply the concrete 
feasibility of such a statement12. According to me, the issue needs a 
further reflection that is able to offer a different interpretation, if 
properly and in-depth discussed. 
                                                 
10 For a panoramic of the vast literature, see TROSOW, Samuel, “Sui Generis 
Database Legislation: A Critical Analysis”, Yale Journal of Law & Technology, 
Yale Law School, Vol. 7, New Heaven, USA, 2005, pp. 534 ff. 
11 Ibidem. 
12 Ex multis, KAYE, Jane/WENDEL, Lotta/HELGASON, Hordur 
Helgi/SILD, Tarmo/NOMPER, Ants, “Population genetic databases: a 
comparative analysis of the law in Iceland, Sweden, Estonia and the UK”, 
Trames, Estonian Academy, Num. 1-2, Tallin, Estonia, 2004, pp. 15 ff.; DG, E. 
C. E., “Report on the Implementation of the European Charter for Small 
Enterprises: Communication from the Commission to the Council and the 
European Parliament”, Office for Official Publications of the European 
Communities, Bruxelles, Belgium, 2005; GIBBONS, Susan/ HELGASON, 
Hordur Helgi/ KAYE, Jane/NOMPER, Ants, “Lessons from European 
Population Genetic Databases: Comparing the Law in Estonia, Iceland, Sweden 
and the United Kingdom”, European Journal of Health Law, Martinus Nijhoff, 
Vol. 12, Leiden, The Netherlands, 2005, pp. 103 ff.; LAURENT, Philippe/ 
VILCHES ARMESTO, Laura, “The intellectual property of medical data: 
copyrights to patients’ records and database rights to biobanks?”, La protection 
des données médicales: les défis du XXIe siècle, HERVEG Jean (Ed.), Anthemis, 
Belgium, 2008, pp. 153 ff.; DE ROBBIO, Antonella/CORRADI, Antonella, 
“Biobanche in bilico tra proprietà privata e beni comuni: brevetti o open data 
sharing?”, JLIS.it, University of Florence, Num. 2, Vol. 1, Firenze, Italy, pp. 305 
ff.; GOEBEL, Jürgen/ PICKARDT, Thomas et al., “Legal and ethical 
consequences of international biobanking from a national perspective: the 
German BMB-EUCoop project”, European Journal of Human Genetics, Nature 
Publishing Group, Num. 5, Vol. 18, New York, USA, 2010, pp. 522 ff.; 
BYGRAVE, Lee, “The Data Difficulty in Database Protection”, University of 
Oslo Faculty of Law Research Paper, n.o 2012-18, 2012, available at 
http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2088018; DOVE, 
Edward/ JOLY, Yann, “The Contested Futures of Biobanks and Intellectual 
Property”, Teorder, McGill University, Num. 11, Montreal, Canada, 2012, pp. 
132 ff. 
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  On the basis of this premise, I aim at demonstrating whether, 
in a de iure condito perspective, the sui generis right can be concretely 
applied to the context of research biobanks. In order to verify this, I 
will firstly analyze the legal framework of database protection, as 
outlined by the European Union law land case law. Secondly, 
through the application of the concepts as resulting from the 
European context. I am going to check whether the research 
biobanks can claim the sui generis right to be referred to their 
collections of biological materials and information. 
 
 
2. The legal protection of the database in Europe. 
 
Directive 96/9/EC has introduced the legal framework for 
databases, articulating the protection according to a double track 
regime13. Besides the protection offered by copyright law (Chap. II), 
the Directive provides a sui generis right to the maker of the database 
(Chap. III)14.  
Copyright protects databases, which «by reason of the 
selection or arrangement of their contents, constitute the author’s 
own intellectual creation» (Article 3). It should be specified that the 
protection is not extended to database content or the existing rights 
over it. So, copyright covers the expression of the database, and the 
originality of its systematic organization. The author’s intellectual 
contribution lies in the level of the handiness of the users’ access and 
                                                 
13 Directive 96/9/EC of the European Parliament and of the Council on the 
legal protection of databases, in O.J.U.C., series L, 27th March 1996, n. 77, p. 20. 
The directive has been transposed by the Legislative Decree 6th May 1999, n. 169, 
amending the Italian Copyright Law (Statute Law n. 633/1941). The directive 
defines the database as «a collection of independent works, data or other 
materials arranged in a systematic or methodical way and individually accessible 
by electronic or other means» (Article 1). This protection cannot be referred to 
«computer programs used in the making or operation of databases accessible by 
electronic means». The provision sprang from the need to avoid normative 
conflicts, in particular, with the directive 91/250/EC on the legal protection of 
computer programs. RONCONI, Franco, “Trapianto e rielaborazione del 
modello normativo statunitense: il diritto d’autore di fronte alla sfida digitale”, I 
diritti sulle opere digitali, PASCUZZI, Giovanni/ CASO, Roberto, CEDAM, 
Italy, 2002, p. 193. 
14 For a deeper analysis, see HUGENHOLTZ, Bernt, “Implementing the 
European Database Directive”, International Intellectual Property Law & Policy, 
Juris Publishing, Vol. 4, New York, USA, 2000, pp. 70 ff.; DAVISON, Mark, 
The Legal Protection of Databases, Cambridge University Press, UK, 2003; 
BEUNEN, Annemarie, Protection for Databases: The European Database 
Directive and Its Effects in the Netherlands, France and the United Kingdom, 
Wolf Legal Publishers, Oisterwijk, The Netherlands, 2007; DERCLAYE, Estelle, 
The Legal Protection of Databases: A Comparative Analysis, Edward Elgar 
Publishing, Cheltenham-Camberley, UK, 2008. 
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in the original disposition of the contents. This goal can be reached 
through the creation of types of data, thesauri, indexing and cross-
reference systems, where the author’s creativity plays a key role15. 
Therefore, if the structure is original, and data are organized in a 
creative manner - for example, not simply alphabetically or 
chronologically ordered - the databases’s author is entitled to the 
moral and economical rights16. The copyright protection of 
databases, as usually, lasts 70 years after the author’s death.  
As one can easily imagine, achieving the standard of 
originality in the database structure is quite difficult. So, in order to 
counterbalance this “thin protection” and to offer a more efficient 
remedy against the ease of the copy permitted by digitization, the 
Directive at stake has introduced a further right – the so called “sui 
generis” – which is granted to the person who takes the initiative and 
the risk of investing (i.e., the maker of the database). 
Such a right is a peculiarity of the EU system and it has been 
introduced with the intent to protect those databases that, 
notwithstanding their originality, have been the fruit of the 
investment of considerable human, technical and financial resources 
and that can be otherwise frustrated by unauthorized access to and 
copy of their elements (Recital 7)17.  
The right which is recognized by the Directive to the maker 
of a database is of utmost importance. The maker can prevent the 
extraction and/or the re-utilization of the whole or of a substantial 
part – which is qualitatively and/or quantitatively evaluated - of the 
contents of that database (Article 7.1). So, the maker of the database 
can inhibit the permanent or temporary transfer of all or a 
substantial part of the contents of a database to another subject by 
any means or in any form, such as the on-screen display of the 
contents (Recital 44). He/She may also transfer, assign or grant 
his/her sui generis right under a contractual license (Article 7.3). 
This right has a hybrid nature: (a) it is unknown in the conceptual 
baggage of copyright and presents profiles of overlapping with 
unfair competition; (b) it does not provide a moral right; (c) it is also 
                                                 
15 IMPERIALI, Riccardo, IMPERIALI, Rosario, “La tutela giuridica delle banche 
dati”, Diritto comunitario e degli scambi internazionali, Editoriale Scientifica, 
Num. 2, Vol. 35, Naples, Italy, 1996, pp. 377. 
16 About the originality’s criteria in the U.S.A. see the leading case Feist 
Publications Inc. v. Rural Telephone Service Co., 499 U.S. 340 (1991). In that 
case, it was ruled out that facts (e.g., an alphabetic list of a telephone directory) 
cannot be subject to copyright law.   
17 There are similar forms of protection in the English and Irish legal system (the 
so-called doctrine of the “sweat of the brow”) and in Scandinavian countries (the 
catalogue rule). See LUBENS, Rebecca, “Survey of Developments in European 
Database Protection”, Berkeley Technology Law Journal, UC Berkeley, Vol. 18, 
Berkeley, USA, 2003, pp. 447 ff. 
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granted to companies and firms; and (d) it does not require a 
minimum standard of creativity18. The only requirements are: (a) the 
investment; (b) the substantiality of the investment which is 
evaluated in qualitative and/or quantitative terms; and (c) the use of 
the investment in the phases of obtaining, verification or 
presentation of the contents19.  
Unfortunately, the Directive does not deepen the description 
of the content of such requirements; therefore this gap has been 
essentially filled both by legal scholars and the case law of the 
European Court of Justice (ECJ).  
Hence, the investment has been broadly interpreted, 
including various sorts of costs such as, for example, the financial 
resources, but also the expenditure of time, effort and energy20. 
Regarding the interpretation of the quantitative and 
qualitative aspect, in 2004 the European Court of Justice (ECJ) has 
clarified that: «the quantitative assessment refers to quantifiable 
resources and the qualitative assessment to efforts which cannot be 
quantified, such as intellectual effort or energy, according to the 7th, 
39th and 40th recitals of the preamble to the directive»21. So, 
basically, the time and the money invested in the database integrate 
the quantitative component, while the effort and energy refer to the 
qualitative component of the substantial investment22. The two 
elements (quantity/quality) have to be considered as an alternative, 
but what is important to stress is that both the terms are related only 
to the type of the investment and not to the quantity or quality of 
the data or elements that are assembled in the database23.  
Lastly, the ECJ has addressed a critical issue regarding the 
                                                 
18 According to the European directive, the beneficiaries of protection under the 
sui generis right can be also companies and firms, as long as «formed in accordance 
with the law of a Member State and having their registered office, central 
administration or principal place of business within the Community; however, 
where such a company or firm has only its registered office in the territory of the 
Community, its operations must be genuinely linked on an ongoing basis with the 
economy of a Member State» (Article 11.2).  
19 Article 7(1). 
20 DERCLAYE, Estelle, The Legal Protection of Databases: A Comparative 
Analysis, Edward Elgar Publishing, UK, 2008, pp.73-75. See also, See European 
Court of Justice 9 November 2004, cases C-46/02 (Fixtures Marketing Ltd v. Oy 
Veikkaus Ab), ECR 2004, p. I-10365; C-338/02 (Fixtures Marketing Ltd v. 
Svenska Spel AB), ECR 2004, p. I-10497; and C-444/02 (Fixtures Marketing Ltd 
v. Organismoa Prognostikon Agnon Podosfairou AE (OPAP), ECR 2004, p. I-
10549; C-203/02 (The British Horseracing Board Ltd and Others/William Hill 
Organization Ltd). 
21 European Court of Justice 9 November 2004, cases C-46/02 (Fixtures 
Marketing Ltd v. Oy Veikkaus Ab), ECR 2004, p. I-10365. 
22 DERCLAYE, Estelle, The Legal Protection of Databases: A Comparative 
Analysis, Edward Elgar Publishing, UK, 2008, p. 91. 
23 Ibidem.  
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function and the types of costs that may count towards the 
investment. Echoing an argument of the so called “spin-off 
theory”24, the ECJ made a precise distinction between the creation 
and the obtaining of data, stating that: «the expression ‘investment in 
… the obtaining … of the contents’ of a database must […] be 
understood to refer to the resources used to seek out existing 
independent materials and collect them in the database, and not to 
the resources used for the creation as such of independent materials. 
The purpose of the protection by the sui generis right provided for by 
the directive is to promote the establishment of storage and 
processing systems for existing information and not the creation of 
materials capable of being collected subsequently in a database»25.  
Some authors justified this conclusion as an attempt to cope 
with a weak point of the Directive, such as the absence of a 
compulsory license regime in the case of sole-source database26. 
However, despite this apparent clarification, the issue of how to 
identify a clear boundary between generating and gathering data can 
be difficult in practice. The question at stake is the following one: is 
the researcher who extracts a genetic sequence from a tissue creating 
or obtaining the information?27. This «quasi-insoluble question»28, 
                                                 
24 The spin-off theory emerged in 1997 in the Dutch case law and it quickly 
spread over other jurisdictions with different fortune. In a nutshell, according to 
this doctrine, only those investments related to the production of the database 
and not to the creation of the data can be protected. In other words, if the 
database is a mere spin-off of the primary activity, i.e., a secondary result which is 
obtained in the context of a broader project, it cannot be eligible for the sui generis 
protection. This conclusion has been explained in the following terms: «the 
database right is not a right of intellectual property rooted in notions of natural 
justice, but a right based on utilitarian (instrumentalist) reasoning. In the light of 
this incentive rationale there would appear to be no reason to grant protection to 
data compilations that are generated quasi ‘automatically’ as by-products of other 
activities». DAVISON, Mark /HUGENHOLTZ, Bernt, “Football fixtures, horse 
races and spin-offs: the ECJ domesticates the database right”, European 
Intellectual Property Review, Sweet and Maxwell, Num. 3 Vol. 27, London, UK, 
2005, pp. 113 ff.; also available at: 
http://www.ivir.nl/publications/hugenholtz/EIPR_2005_3_databaseright.pdf 
25 See European Court of Justice 9 November 2004 cases C-46/02; C-203/02; C-
338/02; C-444/02. For a comment, DERCLAYE, Estelle, “The Court of Justice 
interprets the database sui generis right for the first time”, European Law 
Review, Sweet and Maxwell, Num. 3, Vol. 30, London, UK, 2005, pp. 410 ff. 
26 DERCLAYE, Estelle, “Databases sui generis right: should we adopt the spin 
off theory”, European Intellectual Property Review, Sweet and Maxwell, Num. 9, 
Vol. 26, London, UK, 2004, pp. 402 ff.; DAVISON, Mark /HUGENHOLTZ, 
Bernt, “Football fixtures, horse races and spin-offs: the ECJ domesticates the 
database right”, European Intellectual Property Review, Sweet and Maxwell, 
Num. 3 Vol. 27, London, UK, 2005, pp. 113 ff. 
27 DAVISON, Mark /HUGENHOLTZ, Bernt, “Football fixtures, horse races 
and spin-offs: the ECJ domesticates the database right”, European Intellectual 
Property Review, Sweet and Maxwell, Num. 3 Vol. 27, London, UK, 2005, pp. 
113 ff. 
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which shows a systematic or even philosophical nature, is likely to 
lead us astray. The point is crucial and it will be better addressed in 
more detail in the next paragraph. 
At this level, it is necessary to delineate a final point: even if 
the database is a mere spin-off, this does not a priori exclude the 
validity of the sui generis protection. As the ECJ affirmed, the maker 
of the database can still claim for the sui generis right if he/she proves 
to have made an additional (substantial) investment in the obtaining, 
verification or presentation of the contents, and such investment is 
different of that occurring for the creation of data29. 
Just to conclude with the main features of the sui generis 
provisions, it should be said that the lawful users of a database, in 
the hypothesis in which it is made available to the public, must not 
perform acts which conflict with normal exploitation of the 
database. Moreover, they can neither unreasonably prejudice the 
legitimate interests of the maker of the database, nor cause prejudice 
to the holder of a copyright or related right in respect of the works 
or subject matter which is contained in the database (Articles 8.2 – 
8.3). They can extract or re-use insubstantial parts of the contents of 
the database (Article 8.1), but not in a repeated and systematic way 
(Article 7.5).  
Finally, about the duration, the sui generis right shall expire 15 
years from the 1st January following the date of completion or, in the 
case of a database which is made available to the public, the term of 
protection runs from the 1st January of the year following the date 
when the database was first made available to the public (Article 10). 
The European dual systems of database protection and, 
chiefly, the vagueness of the sui generis right and its scope have raised 
several concerns from a legal point of view30.  
                                                                                                                     
28 DERCLAYE, Estelle, “Databases sui generis right: should we adopt the spin 
off theory”, European Intellectual Property Review, Sweet and Maxwell, Num. 9, 
Vol. 26, London, UK, 2004, pp. 402 ff. 
29 European Court of Justice 9 November 2004, C-203/02 (The British 
Horseracing Board Ltd and Others/William Hill Organization Ltd). 
30 See: DG Internal Market and Services Working Paper, First evaluation of Directive 
96/9/EC on the legal protection of databases, available at 
http://ec.europa.eu/internal_market/copyright/docs/databases/evaluation_rep
ort_en.pdf. It is a right “under supervision”: indeed, every three years the 
Commission shall submit to the European Parliament, the Council and the 
Economic and Social Committee a report on the application of the directive, in 
which, on the basis of specific information supplied by the Member States, it 
shall examine in particular the application of the sui generis right, and it shall verify 
especially whether the application of this right has led to abuse of a dominant 
position or other interference with free competition. If such abuse or 
interference occurs, this would justify the adoption of appropriate measures, 
included the establishment of non-voluntary licensing arrangements. Where it is 
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In particular, the sui generis right has been at the core of the 
debate for its potential negative consequences, such as the perils of 
excessive monopoly, the increased transactions costs, and the 
interference with data aggregation31.  
The educational and research exemption (Article 6) proves 
not to be a sufficient antidote against the danger of the blocking of 
information flow, and, as a matter of fact, the legitimate uses for 
educational or scientific purposes are not even considered by some 
national implementations of the Directive, such as in the case of 
Italy (see Article 102-bis, Statute Law n. 633/41).  
In addition, the 15-year exclusive right recognized to the 
maker of the database looks like the monopoly granted to the patent, 
but it is even more pervasive: through the mechanism of substantial 
changes (Article 10.3), the power to inhibit the extraction or re-use 
can be extended without real time-limits32. This possibility is made 
concrete by the use of technological protection measures (Article 
102-quarter, Statute Law n. 633/41).  
This proprietary regime towards database is able to pose 
serious obstacles to full and open access to data for scientific 
purposes. Both academic and research communities perceived the sui 
generis right as «one of the least balanced and most potentially anti-
competitive intellectual property rights ever created»33.   
The viability of the sui generis right in the field of biobanks - 
which are structures with the institutional goal to promote scientific 
research, balancing the freedom of science/ist with the interest of 
participants and the public - has therefore raised a number of 
concerns. However, in order to allay these fears, it is necessary to 
verify in practice whether all the criteria for the occurrence of the sui 
generis right are fulfilled in the case of research biobanks. 
 
 
 
                                                                                                                     
necessary, the Commission shall submit proposals for adjustment of this 
Directive in line with the developments in the area of databases (art. 16). 
31 TROSOW, Samuel, “Sui Generis Database Legislation: A Critical Analysis”, 
Yale Journal of Law & Technology, Yale Law School, Vol. 7, New Heaven, USA, 
2005, pp. 534 y ss. See also, ICSU, “Report of the CSPR Assessment Panel on 
Scientific Data and Information”, 2004, available at: http://www.science-
softcon.de/cspr.pdf. 
32 IMPERIALI, Riccardo, IMPERIALI, Rosario, “La tutela giuridica delle banche 
dati”, Diritto comunitario e degli scambi internazionali, Editoriale Scientifica, 
Num. 2, Vol. 35, Naples, Italy, 1996, pp. 377. 
33 REICHMAN, Jerome/SAMUELSON, Pamela, “Intellectual Property Rights 
in Data?”, Vanderbilt Law Review, Vanderbilt University, Vol. 50, Nashville, 
USA, 1997, pp. 52 ff. 
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3. Biobanks and the sui generis right: a possible 
relationship? 
 
Biobanks are organizational structures which are aimed at the 
collection of biological materials for research purposes. They are 
formed by a biorepository, where the samples are cryoconservated, 
and an electronic database, within which the “metadata” relating to 
the sample (e.g., tissue type, date of sampling, assigned barcode) are 
indexed, as well as the data which are derived from the analysis 
performed on the same biomaterial. Such data can therefore consist 
of measurements, observations, images, genetic analysis, and 
phenotypic or genotypic information. In the light of their structure, 
biobanks can therefore be considered as a database within the 
definition of Article 1 of the Directive 96/9/EC34. 
Considering the type of materials and the purpose for which 
they are collected, it is difficult to figure out a minimum standard of 
creativity in the organization of the biobank’s database. The samples 
are stored according to the type of pathology, tissue or molecule 
analyzed and they are identified by an alphanumeric code. The data 
contained in the electronic database are sorted according to trivial 
criteria as well. As a result, such databases tend not to meet the 
requirements to be protected under copyright. 
However, creativity is not a precondition for the sui generis 
right. For this reason, this type of right could be referred to the case 
of research biobank’s database. Therefore, it is necessary to check 
whether the substantial investment is in this case aimed at the 
obtainment, verification or presentation of the database’s content. 
As mentioned, the elements of a biobank’s database can lie in 
tissues, biological samples, cells, genetic data, health information, 
and the maker of the biobank indubitably invests a substantial 
amount of resources in order to “have” them. Indeed, it is necessary 
to recruit patients or volunteers to obtain the samples; in some cases, 
the volunteers are paid or compensated; sometimes they have to be 
recontacted; the sample extraction requires different types of costs 
(staff, instruments, etc.), and its following essay has to be performed 
through highly specialized personnel and equipment; and so forth. 
Just to give an idea of the amount of the costs, a small-medium 
biobank collecting less then 600 cases of cancerous tissues requires 
                                                 
34 In fact, the Directive does not protect only the electronic database. According 
to art. 1: «This Directive concerns the legal protection of databases in any form. 
For the purposes of this Directive, 'database` shall mean a collection of 
independent works, data or other materials arranged in a systematic or 
methodical way and individually accessible by electronic or other means». 
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an investment of around 150.000 Euro per year only with reference 
to the hiring of the personnel35. 
The critical point is to understand whether such costs are 
direct to the obtaining of the data rather than to their creation. The 
problem arises because of the peculiar nature of the elements 
collected in a biobank’s database. In fact, on the one hand, biological 
samples and genomic data exist in nature before being extracted or 
processed by a researcher. The human effort does not invent them 
from scratch. On the other hand, such elements pre-exist in nature, 
but in a different way: before the ablation, the biological sample is 
part of the organism, it contributes to its functions, and is not 
possible to identify it as a separate component immersed in 
isopentane36; before the processing, genetic data is a flux of 
information in the form of an encoding biological message and not a 
string of bits. The data are a representation of a natural phenomenon 
and not the phenomenon itself37. They naturally occur in nature, but 
only the human effort is able to translate them in an intelligible 
form, giving them a new shape, a new ontological existence. 
Therefore, according to the stricter interpretation of the term 
“obtaining” as pointed out by the 2004 decisions of ECJ, biological 
samples and data collected in the biobank not are simply gathered, 
but actually created38.  
                                                 
35 The data comes from the example of the Trentino biobank 
(www.tissuebank.it). See also BARBARESCHI, Mattia et al., “Biobanks: 
instrumentation, personnel and cost analysis”, Pathologica, Pacini Editore, Vol. 
100, Ospedaletto (Pisa), Italy, pp. 144 ff. 
36 Isopentane or liquid nitrogen are the most common methods for the 
cryoconservation of samples in a biobank. 
37 DAVISON, Mark/HUGENHOLTZ, Bernt, “Football fixtures, horse races 
and spin-offs: the ECJ domesticates the database right”, European Intellectual 
Property Review, Sweet and Maxwell, Num. 3 Vol. 27, London, UK, 2005, pp. 
113 ff. 
38 Ibidem. Davison and Hugenholtz affirmed the same principles with reference 
to scientific data in general. According to the authors: «While the ECJ appears to 
be confident it can distinguish between ‘creating’ and ‘obtaining’ data, the 
distinction is not always so easy to make. For instance, is the derivation of data 
from naturally occurring phenomena an act of creation or obtaining? One 
example may be the recording of meteorological data such as the daily maximum 
temperature in a particular location. Are those data created or obtained? Similarly, 
do scientists obtain the genetic sequences of living organisms or do they create 
them? The strict approach taken by the ECJ in these four cases would suggest 
that the answer is that such data are created. Meteorological data and genetic 
sequences are records and representations of natural phenomena, not the 
phenomena themselves, and it would be difficult for scientists to argue that they 
have simply collected the data as opposed to creating them. On the other hand, 
when a large mass of such data has been created, there are also significant costs 
associated with presentation and verification, which may meet the requirements 
in Article 7(1) of the Directive. In any event, these metaphysical distinctions will 
undoubtedly continue to concern courts, and commentators for some time to 
come». 
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If we arrive at, and agree with, such a conclusion, the sui generis right 
would vanish as a result, because the investment would not be 
entailed with the obtainment of data.  
Some authors partially disagree with the precedent 
conclusion, arguing that in the case previously shown the substantial 
investment mainly goes into presenting the data in an intelligible 
form, rather than into starting a proper creative process. According 
to Derclaye, scientific data, including the genetic one, are “recorded 
data”, i.e. data not arbitrarily invented but simply reported as 
accurate as possible by man39. In theory, everyone can collect them, 
since they pre-exist in nature, and the intellectual effort lies in the 
presentation of those items. So, such costs have to be considered for 
the evaluation of the substantial investment in the production of the 
database as well. 
However, it should be lastly considered whether the 
investment is aimed at verifying or presenting the data collected in a 
biobank. In fact, even if we admit that the mentioned data are 
"created" within the interpretation of the Directive, there is another 
set of costs related to their presentation and verification. These costs 
refer to: the fact of carrying out the maintenance of the 
biorepository and its cryopreservation system; the supplying of them 
with liquid nitrogen and isopentane to keep a low temperature (- 
80°/170°C) for the preservation of the samples; the issue of enacting 
labeling machines and bar-code readers for the identification of 
samples; procuring instruments for the management of special types 
of tissues; arranging for instruments for the quality control of the 
samples; ordering periodical checks for the maintenance of operating 
standards and procedures; updating the biological samples and data 
with information which has become available in the meantime; 
updating the database platform and website; updating the protection 
measures required by law (these measures are highly strict, as the act 
of processing involves sensitive and genetic data)40. 
Since a substantial investment in verifying and presenting the 
data is due, biobanks are potentially eligible for the sui generis 
protection. At this point, though, it is necessary to address a further 
issue and make a fundamental distinction between the nature, public 
or private, of the biobanking.  
By analyzing the operational reality of this field, we can see 
that the majority of biobanks are public-funded: in some cases they 
                                                 
39 DERCLAYE, Estelle, “Databases sui generis right: should we adopt the spin 
off theory”, European Intellectual Property Review, Sweet and Maxwell, Num. 9, 
Vol. 26, London, UK, 2004, pp. 402 ff. 
40 For more details see BARBARESCHI, Mattia y Otros, “Biobanks: 
instrumentation, personnel and cost analysis”, Pathologica, Pacini Editore, Vol. 
100, Ospedaletto (Pisa), Italy, pp. 144 ff. 
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are a department within a public hospital, in others they are owned 
by universities or set up by non-profit organizations. In Europe the 
percentage of public-funded biobanks reaches the 97%41. 
Directive 96/9/EC does not make any distinction between 
databases owned by a private or public entity. In some jurisdictions 
the sui generis protection is excluded for public databases42. 
Unfortunately, it is not the case of Italy, where Article 102 – bis of 
the national Copyright Law reproduces the ambiguity of the 
Directive. Nevertheless, firstly some authors and then the case law 
have progressively challenged this statement. 
Since the beginning, Italian commentators wondered whether 
the sui generis right could be applied to public databases43. In 
particular, an irresolvable contradiction between the industrial or 
commercial rationale protected by the Directive and the public goals 
pursued by a public administration were highlighted44. So, according 
to these scholars, the sui generis right, at least from a strictly literal 
point of view, cannot work for public databases. 
Furthermore, as affirmed by Dercalye: «in cases where a 
particular database has been made by the state, or in any case 
financed by the state (be it a national or local entity, and be it 
parliament, executive or judiciary), because of the character of its 
producer, irrespective of the nature of the data, and notwithstanding 
that a substantial investment has been made in the obtaining, 
verification or presentation of the data, the database should not 
receive protection. The arguments are close to those underlying the 
spin-off theory. The investment has been recouped; in other words, 
one should not protect the same object twice. Since the taxpayer has 
already paid for the data, he or she should not pay a second time. A 
basis for this argument is not directly apparent in the Directive but it 
should nonetheless be adopted. As a matter of fact, the Directive 
requires a substantial investment. But there is no investment, a fortiori 
                                                 
41 See ZIKA, Eleni y otros, “Biobanks in Europe: Prospects for Harmonisation 
and Networking”, JRC Scientific and Technical Report, European Commission, 
Bruxelles, Belgium, 2010, available at: http://ftp.jrc.es/EURdoc/JRC57831.pdf. 
42 Namely it is the case of France and the Netherlands. DERCLAYE, Estelle, 
“Databases sui generis right: should we adopt the spin off theory”, European 
Intellectual Property Review, Sweet and Maxwell, Num. 9, Vol. 26, London, UK, 
2004, pp. 402 ff. 
43 See SPOLIDORO, Marco Saverio, “Il contenuto del diritto connesso sulle 
banche dati”, AIDA, Giuffrè, Torino, Italy, 1997, pp. 48 y ss.; CHIMIENTI, 
Laura, Banche di dati e diritto d’autore, Giuffrè, Torino, Italy, 1999; 
MEZZETTI, Carlo Eligio, “Banche dati e diritto sui generis. Alcuni profili 
problematici dell’attuazione della Direttiva 96/9/CE”, Quaderni di Palazzo 
Pepoli-Campogrande, Fondazione del Monte di Bologna e Ravenna, Bologna, 
Italy, 2001. 
44 CARDARELLI, Francesco, “Le banche dati pubbliche: una definizione”, 
Diritto dell’informazione dell’informatica, Giuffrè, Torino, Italy, 2002, pp. 321 ff. 
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substantial investment in "state" databases, simply because the 
database has been financed by the taxpayers, and since no risk has 
been taken, no investment has thus been made»45.  
The former (and formal) argument (i.e., the inapplicability of 
the sui generis right to public databases) has been directly confirmed 
by a judicial ordinance issued by the IP section of the Tribunal of 
Rome in 200846. In the case of “Poste Italiane”, ruled out by the 
Italian Court, the national postal service was the owner of "Cerca 
cap" and “Cap Professional”, i.e., two databases containing all the 
Italian postal codes. “Poste Italiane” claimed for an injunction 
against a publishing house in order to block the distribution of the 
catalogue “Codici di avviamento postale” (="Zip codes") and its 
CD-rom, which contained almost the same elements of “Poste 
Italiane” databases. The Tribunal stated that the Italian legislation 
(Article 102-bis L. 633/41) recognizes a right to the maker of the 
database consisting in the power to prohibit the extraction or re-
utilization of all or a substantial part of the contents of that database; 
however the Court emphasized that such right belongs to the 
citizens or to the companies of a Member State. Since the Public 
Administration does not belong to these categories, it cannot be 
protected under the sui generis right and the claim of “Poste 
Italiane” has to be rejected.  
Therefore, there are a series of doctrinal and judicial 
arguments that lead to the conclusion that a public biobank cannot 
exercise the sui generis right. 
Then, what about private biobanks? The question can be 
answered once again by taking into account the reality of the 
biobanking rather than focusing on a hypothetical situation. As seen, 
the number of private biobanks in Europe is extremely scarce. 
Furthermore, these few examples are not exclusively aimed at 
offering a service of “pure” collection and preservation of data for 
themselves, but the databases are the biobanks’ in-house resource 
used for the development of the biobanks’ own research projects. 
The investments of such biobanks are not primarily addressed to the 
creation of a database, but the latter is generated automatically as by-
products of a broader activity. 
There are, thus, all the conditions for the application of the 
still popular “spin-off doctrine”, according to which there would not 
be any incentive in granting a sui generis protection for an incidental 
                                                 
45 DERCLAYE, Estelle, “Databases sui generis right: should we adopt the spin 
off theory”, European Intellectual Property Review, Sweet and Maxwell, Num. 9, 
Vol. 26, London, UK, 2004, p. 408. 
46 Tribunale di Roma, Sez. IP, ordinanza 5 giugno 2008, Edizioni Cierre s.r.l. v. 
Poste Italiane s.p.a. 
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result of other activities47. 
The criteria to filter the application of the spin-off theory in 
the case of “recorded data” have been effectively synthesized by 
Dercalye in the following terms: «if the main activity is to present the 
data, the substantial investment is in collecting and presenting the 
data for themselves. Therefore the spin-off doctrine does not apply 
since there is no other activity with which the collector can recoup 
its investment […] If the main activity is not to present the data but 
to understand the functioning of nature, be it the universe or living 
beings, then it can be said that the data generated are a by-product of 
this main activity. In this case, the spin-off theory would apply»48.  
In all the cases where there is a private biobank, this occurs 
because there is a company or an industry that generates the 
databases as a result of a more extensive research project. If the 
company “X” wants to find a genetic variation linked to ovarian and 
breast cancer, then the company will collect a cohort of biological 
samples and derive a set of data within a research project with the 
purpose to obtain a patent. In this case, the database is just a 
consequence, or an intermediate step, of a broader plan. Hence, 
since the primary activity of a private biobank is the applied research 
and it is not limited to the collection and presentation of the data 
themselves, very few and narrow spaces remain considerable for the 
application of the sui generis right. 
 
 
4. Conclusion 
 
The sui generis right is a very pervasive proprietary tool, which 
can dangerously undermine the free movement of information and 
the progress of knowledge. Especially in the field of biomedical 
research, the intense enforcement of such right may lead to a 
stalemate, as it restricts the access to resources of pre-competitive 
nature, which represent the building block for any investigation. 
This risk is strongly perceived in the context of research 
biobanks. Their institutional goal, as internationally recognized, 
should be to provide resources to researchers in order to foster the 
understanding of human health and the disease’s molecular 
development. So, each restriction to such sharing should be 
                                                 
47 See DAVISON, Mark /HUGENHOLTZ, Bernt, “Football fixtures, horse 
races and spin-offs: the ECJ domesticates the database right”, European 
Intellectual Property Review, Sweet and Maxwell, Num. 3 Vol. 27, London, UK, 
2005, pp. 113 ff. 
48 DERCLAYE, Estelle, “Databases sui generis right: should we adopt the spin 
off theory”, European Intellectual Property Review, Sweet and Maxwell, Num. 9, 
Vol. 26, London, UK, 2004, p. 411. 
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considered in contrast with the essential aim of a biobank and, as a 
consequence, IPRs, included the sui generis right, could not be 
invoked. 
Nevertheless, the sui generis protection cannot apply in this 
case for at least two reasons. Firstly, all the data that are collected 
both in the biorepository and in the electronic database are actually 
created by the maker of the biobank. So, according to the strict 
interpretation given by the ECJ, the substantial investment done in 
this phase cannot be eligible for a sui generis protection. 
Secondly, even assuming that such data are not created and 
that a biobank invests substantially at a later stage which is 
exclusively related to the verification or presentation of the data, 
however, the sui generis right could not be applied. Public biobanks, 
in fact, cannot be protected on the basis of both a formal and an 
economic argument: on the one hand, a public biobank cannot be 
considered as citizen or companies of a Member State in compliance 
with the Directive’s provisions; on the other hand, the activity 
pursued by public administration entails no commercial risk by 
definition, and thus, considering the rationale of the Directive, there 
is no incentive in order to protect any investment. Furthermore, the 
sui generis right cannot apply to private biobanks: their databases are 
not a primary activity, and, applying the spin-off doctrine, they do 
not benefit of any type of protection. 
In conclusion, the "terrible" sui generis right is unable to 
damage the data sharing in the biobanks’ framework. Indeed, none 
of the makers of a database can legally enforce such a right. 
However, this does not mean that this area is free from obstacles to 
the knowledge’s access: the crucial issue, which has still to be solved 
by lawyers, refers to the restrictions on the access of knowledge, 
which are imposed by contracts, by the licensing and the 
technological measures. 
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